{"id":390108,"date":"2021-02-11T00:00:00","date_gmt":"2021-02-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2020-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-24T11:26:46","modified_gmt":"2026-04-24T11:26:46","slug":"dlsfon0008-2020-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2020-biopharma-prostate-cancer-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Prostate Cancer | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &#038; Johnson \/ Janssen Biotech \/ Janssen-Cilag \/ AstraZeneca) and Xtandi (Pfizer \/ Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). However, the use of second-generation hormonal agents has expanded beyond mCRPC, and they are being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson &#038; Johnson\u2019s Zejula and Pfizer\u2019s Talzenna), three immune checkpoint inhibitors (Bristol Myers Squibb \/ Ono Pharmaceutical\u2019s Opdivo, Bristol Myers Squibb \/ Ono Pharmaceutical\u2019s Yervoy, Merck Sharp and Dohme\u2019s Keytruda), two kinase inhibitors (Array BioPharma \/ Roche \/ Genentech \/ Chugai\u2019s ipatasertib and AstraZeneca\u2019s capivasertib), one radioligand therapy (Novartis\u2019s 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis \/ Takeda \/ Ipsen\u2019s Cabometyx) in Phase III development.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?<\/li>\n<li>How is prostate cancer currently managed, and how will treatment practices change in the future?<\/li>\n<li>What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2029?<\/li>\n<li>What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research: <\/strong>More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Key companies<\/strong>: Johnson &#038; Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp &#038; Dohme, Exelixis, Ipsen, Takeda, AstraZeneca, Bristol Myers Squibb, Ono Pharmaceutical, Novartis, Myovant Sciences.<\/p>\n<p><strong>Key drugs: <\/strong>Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Cabometyx (cabozantinib), ipatasertib, relugolix, 177Lu-PSMA-617, capivasertib.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390108","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390108\/revisions"}],"predecessor-version":[{"id":576450,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390108\/revisions\/576450"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}